Previous 10 | Next 10 |
home / stock / grts / grts articles
ATLANTA, June 10, 2024 (GLOBE NEWSWIRE) -- A shareholder class action lawsuit has been filed against Gritstone bio, Inc. ("Gritstone" or the "Co...
Shares of Diodes Incorporated (NASDAQ:DIOD) fell sharply during Friday's session after the company reported worse-than-expected quarterly fina...
Shares of Natera, Inc. (NASDAQ:NTRA) rose sharply in today's pre-market trading following strong first-quarter earnings. Natera posted GAAP lo...
EMERYVILLE, Calif., April 29, 2024 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (NASDAQ:GRTS), a clinical-stage biotechnology company working to deve...
Over the past twenty days of trading, Gritstone Oncology Inc. (NASDAQ: GRTS), from March 05, 2024 to April 02, 2024 there is a potential Short Squ...
U.S. stocks traded lower toward the end of trading, with the Nasdaq Composite dipping over 1% on Tuesday. The Dow traded down 1.07% to 39,142.53 wh...
Shares of Stryve Foods, Inc. (NASDAQ: SNAX) fell sharply during Tuesday’s session following a fourth-quarter revenue miss. Stryve Foods post...
U.S. stocks traded lower midway through trading, with the Nasdaq Composite falling more than 1% on Tuesday. The Dow traded down 1.05% to 39,152.47 ...
U.S. stocks traded lower this morning, with the Dow Jones index falling more than 400 points on Tuesday. Following the market opening Tuesday, the ...
News, Short Squeeze, Breakout and More Instantly...
Gritstone Oncology Inc. Company Name:
GRTS Stock Symbol:
NASDAQ Market:
Gritstone Oncology Inc. Website:
2024-06-14 13:15:03 ET JMP Securities analyst issues MARKET OUTPERFORM recommendation for GRTS on June 14, 2024 11:01AM ET. The previous analyst recommendation was Market Outperform. GRTS was trading at $0.7575 at issue of the analyst recommendation. The overall analyst ...
2024-05-24 11:30:04 ET B. Riley analyst issues BUY recommendation for GRTS on May 24, 2024 09:31AM ET. The previous analyst recommendation was Buy. GRTS was trading at $0.8039 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analys...
-- Favorable progression-free survival (PFS) trend observed in preliminary data from the randomized Phase 2 study evaluating GRANITE (personalized neoantigen vaccine) in front-line metastatic, microsatellite-stable colorectal cancer (MSS-CRC); mature PFS data expected in the third quarter of 2024...